Endothelial control of vascular tone in large and small coronary arteries  by Lüscher, Thomas F. et al.
JACC Vol. 15, No. 3 
March I, 1990:519-25 
519 
Endothelial Control of Vascular Tone in Large and Small 
Coronary Arteries 
THOMAS F. LUSCHER, MD, FESC, VINCENT RICHARD, PHD, MARCEL TSCHUDI, BSc, 
ZHIHONG YANG, MD, CHANTAL BOULANGER, PHD 
Basel, Switzerland 
The endothelium modulates coronary vascular tone by the 
release of endothelium-derived relaxing or contracting sub- 
stances. The endothelium-derived relaxing factor has been 
identified as nitric oxide synthesized in endothelial cells 
from L-arginine. The endothelium can release other relax- 
ing substances such as prostacyclin and a hyperpolarizing 
factor. Endothelin-1 is a potent vasoconstrictor peptide 
formed by endothelial cells, and is likely to be the physio- 
logic antagonist of endothelium-derived relaxing factor. 
Other putative contracting factors include superoxide an- 
ions and products of arachidonic acid metabolism. 
Endothelium-derived relaxing factor is released sponta- 
neously and in response to flow, platelet-derived products 
(that is, serotonin, thrombin and adenosine diphosphate) 
and certain autacoids (that is, acetylcholine, bradykinin, 
histamine, substance P, vasopressin, alpha-adrenergic ag 
onists). A considerable heterogeneity of responses exists 
among vessels of different size from different anatomic 
origin and different species. Hypercholesterolemia, athero- 
sclerosis, hypertension and myocardial &hernia or reper- 
fusion, or both, impair endothelium-dependent relaxation. 
Under normal conditions, endothelium-derived relaxing 
factor appears to dominate the control of vascular tone of 
large and small coronary vessels, whereas in disease states, 
endothelium-derived contracting factors are released. Im- 
pairments of endothelial function may be important in the 
development of various forms of cardiovascular disease. 
(J Am Co11 Cardiol1990;15:519-27) 
Since the pioneering work of Furchgott and Zawadzki (I), it 
has been recognized that the endothelium plays a crucial role 
in the control of vascular tone through the production of 
endothelium-derived relaxing and contracting factors (Fig. I) 
(2-6). The endothelium is also involved in hemostasis and is 
a primary target of cardiovascular disease. This report up- 
dates previous reviews on the endothelial control of vascular 
tone (5,6) and focuses on endothelium-dependent responses 
in large and small coronary arteries in health and disease. 
Endothelium-Derived Vasoactive Substances 
Endothelium-derived relaxing factor (EDRF). In isolated 
arteries, the relaxation induced by acetylcholine is endothe- 
lium-dependent (Fig. 2) (1,7). Bioassay experiments have 
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demonstrated that the response is mediated by a diffusible 
substance with a half-life of a few seconds. The release of 
endothelium-derived relaxing factor can be triggered by 
shear stress (flow), a number of autacoids including brady- 
kinin, histamine, noradrenaline, substance P, vasopressin (in 
certain arteries), platelet-derived products (adenosine di- 
and triphosphate [ADP and ATP], serotonin, thrombin) and 
the calcium ionophore A23187 (Fig. 1) (7-15). Endothelium- 
derived relaxing factor evokes relaxation of vascular smooth 
muscle and inhibits platelet function (1,16,17) through acti- 
vation of soluble guanylate cyclase, which leads to an 
increase in the intracellular levels of cyclic 3’S’ guanosine 
monophosphate (GMP) (18,19). 
Because nitrates have a similar mode of action, this 
suggested that endothelium-derived relaxing factor may rep- 
resent an endogenous nitrate (20,21). Indeed, cultured endo- 
thelial cells release nitric oxide from L-arginine in sufficient 
amount to account for the endothelium-dependent relaxation 
evoked by bradykinin. Exogenous nitric oxide has a half-life, 
mode of action and vascular effect similar to those of 
endothelium-derived relaxing factor (22-24). The release of 
endothelium-derived relaxing factor from cultured endothe- 
lial cells and the endothelium-dependent relaxation observed 
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Figure 1. Endothelium-derived vasoactive substances. 
AA = arachidonic acid; ACE = angiotensin-converting 
enzyme; ACh = acetylcholine; ADP = adenosine 
diphosphate; ATG = angiotensinogen; AT141 = angio- 
tensin I/II; cAMP/cGMP = cyclic adenosine/guanosine 
monophosphate; EDCF = endothelium-derived con- 
stricting factor; EDHF = endothelium-derived hyperpo- 
larizing factor; 5-HT = 5-hydroxytryptamine (seroto- 
nin); K+ = potassium; M = muscarinic receptor; Na+ = 
sodium; NO = nitric oxide; P, = purinergic receptor; 
PGI, = prostacyclin; S, = 5-HT,-serotonergic receptor; 
T = thrombin receptor; V = vasopressinergic receptor. 
(Modified from Liischer [5,61, with permission.) 
in isolated arteries can be blocked by the analogue of 
L-arginine, L-NG-monomethyl arginine (L-NMMA), which 
competes with the precursor of nitric oxide for the specific 
enzyme (Fig. 3) (25; Yang and Ltischer, unpublished data). 
Prostacyclin (PGI,). Endothelial cells are a rich source of 
prostacyclin (26,27). Prostacyclin relaxes large coronary 
arteries, increases coronary flow and inhibits platelet aggre- 
gation (26). The mechanism of action of prostacyclin in- 
volves an increase in cyclic 3’,5’ adenosine monophosphate 
Figure 2. Endothelium-dependent relaxation in response to acetyl- 
choline (Ach.) in a human internal mammary artery (original record- 
ing). NE = norepinephrine. The relaxation to acetylcholine can be 
reversed by hemoglobin (Hb 10e5 M; upper panel). (Reprinted from 
Ltlscher et al. [7], with permission.) 
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(AMP) (Fig. 1) (26). The production of prostacyclin is 
activated by shear stress, hypoxia and various autacoids that 
release endothelium-derived relaxing factor (28-30). How- 
ever, in most blood vessels, prostacyclin contributes very 
little to endothelium-dependent relaxation. Subthreshold 
concentrations of prostacyclin can augment the antiaggrega- 
tory and relaxing effects of endothelium-derived relaxing 
factor in platelets and vascular smooth muscle (16,3 1). 
Other endothelium-derived relaxing factors. In addition to 
nitric oxide, the endothelium releases a hyperpolarizing 
factor (EDHF) (Fig. 1) (32). Acetylcholine causes endothe- 
lium-dependent increases in membrane potential, which are 
blocked by the sodium/potassium adenosine triphosphatase 
inhibitor ouabain, whereas nitric oxide does not hyperpolar- 
ize smooth muscle cells (32,33). Ouabain reduces endotheli- 
urn-dependent relaxation in certain blood vessels (34,35). 
Endothelium-derived hyperpolarizing factor may contribute 
to endothelium-derived relaxing factor-induced relaxation 
and reduce the sensitivity of the cells to vasoconstrictor 
hormones. 
Endothelium-derived contracting factors. Under some 
conditions such as hypoxia and after activation by stretch 
and certain autacoids, endothelial cells can release endothe- 
lium-derived contracting factors (EDCFs) (Fig. 1) (36-38). 
In the canine femoral artery with endothelium, anoxia facil- 
itates contractions to noradrenaline and potassium chloride 
(36). In canine coronary arteries, hypoxia releases an endo- 
thelium-derived contracting factor (EDCF,) (37). The re- 
sponse is resistant to most pharmacologic interventions and, 
in particular, to inhibitors of cyclooxygenase, but can be 
blocked by calcium channel antagonists (39,40). In certain 
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blood vessels, arachidonic acid and acetylcholine evoke 
endothelium-dependent contractions blocked by indometh- 
acin or meclofenamate, suggesting that they are mediated by 
a cyclooxygenase-dependent contracting factor (EDCF,) 
(Fig. 1) (35,38-43). Because attempts to bioassay cycloox- 
ygenase-dependent contracting factor have failed, it is likely 
that oxygen-derived free radicals or a very labile endoper- 
oxide intermediate are involved (44). Indeed, in the canine 
basilar artery, superoxide evokes increases in tension and 
superoxide dismutase inhibits endothelium-dependent con- 
tractions (44). 
Recently, Yanagisawa et al. (45) isolated the vasocon- 
strictor peptide endothelin produced by endothelial cells in 
culture (46,47). Although three isomers of endothelin have 
been characterized to date, only one (endothelin-1) has so far 
been shown to be released from endothelial cells (48). 
Endothelin-1 is a 21 amino acid peptide that is formed and 
released from endothelial cells in culture and intact arteries 
on stimulation with thrombin, transforming growth factor p, 
noradrenaline, phorbol ester and the calcium ionophore 
A23187 (45,48-51). In vivo, the circulating levels of the 
peptide are extremely low (52). In vascular smooth muscle, 
endothelin-1 binds to specific membrane receptors and in- 
duces an increase in intracellular calcium and long-lasting 
contractions (53). The peptide has a greater vasoconstricting 
potency than any other cardiovascular hormone (45,54-56). 
In most preparations, endothelium-derived relaxing factor or 
nitrovasodilators inhibit contractions induced by endothelin- 
1, whereas calcium antagonists are less effective in most 
blood vessels (56-59). It is unlikely that endothelin-1 is 
identical to the contracting factor released during hypoxia 
(37,59). 
Other endothelium-derived substances. The endothelium 
can synthesize agents involved in hemostasis such as anti- 
thrombin III, von Willebrand factor, urokinase and tissue 
plasminogen activator (t-PA) as well as procoagulatory fac- 
tors (60). Tissue plasminogen activator (which stimulates 
fibrinolysis) is released from endothelial cells in culture on 
stimulation by thrombin, adrenalin, bradykinin and platelet- 
Acetylcholine (-IogM) 
activating factor (61,62). Thus, most substances releasing 
endothelium-derived relaxing factor and prostacyclin from 
endothelial cells also stimulate the formation of tissue plas- 
minogen activator, suggesting that these substances form a 
protective system against vasospasm and thrombus forma- 
tion (Fig. 1) (6,16,17,19,63). 
Endothelial cells can produce heparinlike growth inhibi- 
tors (64,65) as well as growth factors such as platelet-derived 
growth factor (PDGF) and thrombospondin (66). Stimulation 
of cyclic guanosine monophosphate by nitric oxide or so- 
dium nitroprusside inhibits mitogenesis and proliferation of 
vascular smooth muscle cells in culture, suggesting that 
endothelium-derived relaxing factor might exert an antipro- 
liferative effect (67). 
Endothelial Control of Large 
Coronary Arteries 
Physiology. Although endothelium-dependent relax- 
ations have been described in a number of species and blood 
vessels, a considerable heterogeneity exists among vascular 
beds and species. Thus, although canine coronary arteries 
relax in response to acetylcholine, the muscarinic agonist 
induces contractions in the pig, sheep and cattle (Fig. 4) 
(68,69). In the human coronary artery, some investigators 
(70) reported consistent relaxation and increases in cyclic 
guanosine monophosphate, whereas others (71,72) observed 
relaxation only in a few preparations (although all relaxed to 
substance P or the calcium inophore A23187) or consistent 
contractions (68). Possibly, muscarinic responses are lost 
early on in coronary disease or relaxations are difficult to 
demonstrate in isolated rings because acetylcholine simulta- 
neously activates receptors that are inhibitory on the endo- 
thelium and those that are excitatory on vascular smooth 
muscle. Indeed, selective intraarterial infusion of acetylcho- 
line causes coronary vasodilation in vivo (73). 
Aggregating platelets induce endothelium-dependent re- 
laxation in coronary arteries of the pig, dog and human 
(13,15,74-76). The nature of the platelet-derived mediator, 
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however, differs among species. In dogs and humans, aden- 
osine diphosphate is responsible, whereas in pigs, serotonin 
accounts for the relaxation (13,14,74-76). In the dog and pig 
(in the presence of ketanserin), serotonin causes endotheli- 
urn-dependent relaxations, but it does not release endothe- 
lium-derived relaxing factor in human arteries obtained from 
transplant recipients (13,15,72,74,75). Thrombin that is 
formed at sites where platelets are activated can release 
endothelium-derived relaxing factor in porcine and canine 
arteries (74,75,77). The release of endothelium-derived re- 
laxing factor may represent a negative feedback mechanism 
preventing vasospasm and thrombus formation at sites 
where platelets are activated. 
Other mediators. Other substances causing endothelium- 
dependent relaxation in coronary arteries include histamine, 
bradykinin and substance P (14,74,75,78-82). In contrast to 
coronary arteries in the pig and dog, human coronary 
arteries do not express endothelial alpha-adrenergic recep- 
tors linked to the release of endothelium-derived relaxing 
factor (8,72). 
Coronary artery disease. Coronary vasospasm most 
likely involves a local dysfunction of the vascular wall that 
could be related to a hyperreactivity of vascular smooth 
muscle or to dysfunction of the endothelium, or both (83,84). 
Indeed, although acetylcholine normally causes relaxation of 
human coronary arteries, the substance can provoke coro- 
nary spasm in patients with coronary artery disease (73,85). 
In porcine coronary arteries, in vivo endothelium re- 
moval is followed by rapid regeneration of the endothelium 
and recovery of endothelium-dependent relaxation within 1 
week (74). However, 4 weeks after the intervention, endo- 
thelium-dependent relaxation in response to platelets and 
serotonin is reduced and the contraction in response to 
serotonin is enhanced. Under these conditions, in vivo 
activation of circulating platelets with adenosine diphos- 
phate can provoke coronary spasm at the site of previous 
endothelial injury (Shimokawa and Vanhoutte, unpublished 
observations). 
Histamine can provoke coronary vasospasm in certain 
patients with variant angina and in pigs after endothelial 
--b 
9 0 I 6 
Histamine (-IogM) 
Figure 4. Endothelium-dependent relax- 
ations in response to acetylcholine, sub- 
stance P and histamine in normal (0) and 
atherosclerotic (0) human coronary arter- 
ies. Note the impaired response in dis- 
eased arteries. *Denotes statistically sig- 
nificant difference (p < 0.05). (Reprinted 
from Vanhoutte and Houston [63] with 
permission.) 
denudation in conjunction with an atherogenic diet (86,87). 
In patients with coronary artery disease, the vascular hista- 
mine content is increased (88). Coronary artery mast cell 
infiltration can occur in patients with spasm (89). Thus, at 
sites of a decreased release of endothelium-derived relaxing 
factor, direct contractile effects of histamine may precipitate 
vasospasm. 
Ischemia and reperfusion. In isolated arteries, hypoxia or 
anoxia inhibits the release of endothelium-derived relaxing 
factor and, at least in the canine coronary artery, stimulates 
release of an endothelium-derived contracting factor 
(EDCF,) (36,37). Ischemia can injure blood vessels and 
induce endothelial cell swelling (90,91) and obstruction of 
capillaries with neutrophils (92), which can lead to regional 
reperfusion defects (that is, “no reflow phenomenon”) (91). 
Postischemic reperfusion is associated with accelerated 
structural degradation of endothelial cells and increased 
neutrophil adhesion and accumulation (91,93,94). In canine 
and porcine coronary arteries, endothelium-dependent re- 
laxation in response to most agonists is attenuated after 
ischemia and reperfusion, whereas contractile properties 
remain unaltered (Fig. 5) (77,93,95-98; Richard et al., un- 
published observations). Relaxation in response to nitrova- 
sodilators can be unaltered (95) or reduced (96). In the dog, 
the impaired endothelium-dependent relaxation in response 
to aggregating platelets persists up to 3 months after the 
injury, whereas that in response to acetylcholine recovers 
(98). 
This ischemia or reperfusion injury, or both, of the 
endothelium could be mediated by oxygen-derived free 
radicals produced in the reperfused myocardium or endothe- 
lial cells (99). Indeed, superoxide anions inactivate endothe- 
lium-derived relaxing factor and contract certain blood ves- 
sels (44,100). Superoxide dismutase may prevent endothelial 
dysfunction after ischemia and reperfusion (101). In endo- 
thelial cells in culture, free radicals are formed (mainly 
through xanthine oxidase) during postanoxic reoxygenation 
in amounts sufficient to kill most of the cells, whereas 
superoxide dismutase prevents cell death (102). The reduced 
release of endothelium-derived relaxing factor after ischemia 
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Figure 5. Effect of ischemia and reperfusion on endothelium- 
dependent relaxation in response to serotonin in porcine coronary 
arteries. Pigs were subjected to 30 min occlusion of the distal third 
of the left anterior descending coronary artery, followed by reper- 
fusion for 30 min. Rings were incubated with ketanserin for 45 min 
before the experiment to inhibit 5-HT,-serotonergic receptors on the 
vascular smooth muscle. PGF,, = prostaglandin F,,. (From Rich- 
ard et al., unpublished observations, with permission.) 
and reperfusion may contribute to the recurrence of vaso- 
spasm and thrombus formation, particularly in patients with 
unstable angina. 
Cardiovascular risk factors. Hyperlipidemia, hyperten- 
sion and diabetes attenuate endothelium-dependent relax- 
ation in various blood vessels (7,103). Low density lipopro- 
teins reduce endothelium-dependent relaxation of the 
isolated rabbit aorta and the release of endothelium-derived 
relaxing factor from cultured endothelial cells (104,105). In 
the porcine coronary artery, hypercholesteremia moderately 
attenuates endothelium-dependent relaxation in response to 
aggregating platelets, serotonin and adenosine diphosphate, 
but not in response to bradykinin, thrombin and the calcium 
ionophore A23 187 (76). This suggests that hyperlipidemia 
interferes with some but not all receptor-operated mecha- 
nisms for the release of endothelium-derive%1 relaxing factor. 
Atherosclerosis. Atherosclerosis reduces endothelium- 
dependent relaxation and promotes endothelium-dependent 
contraction. For example, in the porcine coronary artery, 
atherosclerosis impairs relaxation induced by platelets, ser- 
otonin, adenosine diphosphate, thrombin, bradykinin, sub- 
stance P and the calcium ionophore A23187, indicating 
impaired production and release of endothelium-derived 
relaxing factor (76,106). Under bioassay conditions, the 
serotonin-induced release of endothelium-derived relaxing 
factor is reduced in porcine coronary arteries with athero- 
sclerosis (76). In addition, serotonin evokes endothelium- 
dependent contractions that can be prevented by indometh- 
acin, indicating the release of a cyclooxygenase-dependent 
contracting factor (EDCF,) (76). Similarly, in isolated ath- 
erosclerotic human arteries, endothelium-dependent relax- 
ation in response to acetylcholine, bradykinin, histamine, 
substance P, adenosine diphosphate and aggregating plate- 
lets is reduced (14,70,72). The response to the calcium 
ionophore A23187 may be reduced (14,76) or unimpaired 
(70), indicating that the receptor-operated release of endo- 
thelium-derived relaxing factor by the autacoids is affected 
earlier in the process of atherosclerosis than the production 
of the factor (as evidence by the effect of A23187). In 
patients with coronary artery disease, infusion of acetylcho- 
line in the left anterior descending coronary artery induces 
paradoxic contractions, suggesting that endothelial dysfunc- 
tion occurs in patients with coronary artery disease in vivo 
(73). 
Endothelial Control of Small 
Coronary Arteries 
Response of proximal versus distal coronary segments. 
Small arteries (with a diameter of 5300 pm) play an impor- 
tant role in the regulation of peripheral vascular resistance 
and coronary flow. Although endothelium-dependent relax- 
ations have been demonstrated in resistance arteries from 
various vascular beds, the response can differ considerably 
as compared with that in large arteries (107-109). In the 
coronary artery of the dog, the responsiveness to the dif- 
ferent endothelium-derived relaxing factors changes from 
the proximal to the distal part of the blood vessel (110). 
Under bioassay conditions, distal segments relax more in 
response to the endothelium-derived relaxing factor released 
under basal conditions (from a femoral artery) than proximal 
segments, whereas the responses to the endothelium-derived 
relaxing factor released by acetylcholine or to nitrovasodi- 
lators do not differ (110). Because the relaxing factor re- 
leased under flow-stimulated conditions most likely differs 
from nitric oxide (11 l), this would suggest that the sensitivity 
of coronary smooth muscle to other relaxing factors (such as 
endothelium-derived hyperpolarizing factor) increases from 
proximal to distal segments of the coronary circulation. 
In isolated perfused hearts of the rabbit and rat, acetyl- 
choline and serotonin reduce coronary perfusion pressure or 
increase coronary flow (112,113). Because these effects can 
be reversed by hemoglobin or generation of oxygen-derived 
free radicals, the autacoids most likely release endothelium- 
derived relaxing factor in coronary resistance vessels 
(114,115). In line with this interpretation, endothelium- 
derived relaxing factor released by acetylcholine from 
freshly harvested cultured endothelial cells increases coro- 
nary blood flow in isolated rabbit hearts (116). In anesthe- 
tized dogs, intracoronary administration of acetylcholine or 
bradykinin increases regional myocardial blood flow prefer- 
entially in subendocardial regions (117-I 19). Thus, suben- 
docardial coronary resistance arteries may either release 
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Figure 6. Effects of bradykinin in porcine coronary resistance 
vessels (internal diameter 300 pm) with and without endothelium, 
contracted with acetylcholine (Ach). Abbreviations as in Figure 3. 
(From Tschudi et al., unpublished observations, with permission.) 
more of the factor or their vascular smooth muscle may be 
more responsive to it. 
Vasotonic responses in the coronary resistance arteries. 
Isolated coronary resistance vessels of the rabbit relax in 
response to acetylcholine, adenosine diphosphate or nitric 
oxide (120). In isolated porcine coronary resistance vessels, 
acetylcholine produces potent contractions (Fig. 6) (121; 
Tschudi et al., unpublished observations). Because hemo- 
globin and the analogue of L-arginine (L-NMMA) augment 
contractions in rings with endothelium, the resistance arter- 
ies may continuously release endothelium-derived relaxing 
factor to modulate the response to vasoconstrictors (122; 
Tschudi et al., unpublished observations). In porcine coro- 
nary resistance vessels precontracted with acetylcholine, 
bradykinin induces potent endothelium-dependent relax- 
ations (Fig. 6) (121; Tschudi et al., unpublished observa- 
tions). Serotonin and aggregating platelets can also induce 
relaxations in this preparation (Tschudi et al., unpublished 
observations). Because L-NG-monomethyl arginine and 
methylene blue (which inhibits the formation of cyclic gua- 
nosine monophosphate) only reduce but do not prevent the 
relaxations induced by bradykinin, the endothelium of por- 
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Figure 7. Effects of serotonin on coronary flow in isolated hearts 
perfused by the Langendoti technique from normotensive Wistar- 
Kyoto rats (WKY) and spontaneously hypertensive rats (SHR). 
*Statistically significant difference between WKY and SHR 
(p 5 0.05). (Modified from Liischer et al. [113], with permission.) 
tine coronary resistance arteries may release more than one 
relaxing factor (Tschudi et al., unpublished observations). 
Fish oil. As in large coronary arteries of the pig (75), 
bradykinin-induced relaxations are augmented in pigs sub- 
jected to a diet rich in polyunsaturated fatty acids (121). 
Hypertension and atherosclerosis. In isolated rat hearts, 
serotonin increases coronary flow in normotensive rats, but 
produces a marked decrease in flow in spontaneously hyper- 
tensive rats (Fig. 7) (113). This contraction induced by 
serotonin can be prevented by indomethacin, suggesting the 
release of a cyclooxygenase-dependent contracting factor 
(EDCF,) in coronary resistance arteries of hypertensive 
animals (113). 
In isolated coronary resistance vessels obtained from 
cholesterol-fed rabbits, the relaxations in response to ace- 
tylcholine and adenosine diphosphate are abolished, 
whereas the response to nitric oxide is unaltered, suggesting 
a selective defect in the synthesis or release of endothelium- 
derived relaxing factor (120). 
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